References

Cost effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial

10.3111/200306055068 · 2003 · External reference

Cost-effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis

10.2165/11317730-000000000-00000 · 2009 · External reference

Stimulating pharmaceutical innovation in the EU

10.1586/erp.11.19 · 2011 · External reference

Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece

10.1016/j.clinthera.2012.07.002 · 2012 · External reference

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

10.1136/thx.2007.090647 · 2008 · External reference

Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice

10.1111/bcp.12116 · 2014 · External reference

Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea

10.1111/j.1524-4733.2009.00631.x · 2009 · External reference

Varenicline as compared to bupropion in smoking-cessation therapy — cost-utility results for Sweden 2003

10.1016/j.rmed.2007.12.018 · 2008 · External reference

Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation — results from four European countries

10.1093/eurpub/ckp075 · 2009 · External reference

Management of COPD in Belgium: a real life cost of illness [poster]

2005 · External reference

Pharmacological interventions for smoking cessation: an overview and network meta-analysis

10.1002/14651858.cd009329.pub2 · 2013 · External reference

Cigarette smoking and ozone-associated emergency department use for asthma by adults in New York City

10.1164/ajrccm.159.6.9809042 · 1999 · External reference

Belgian guidelines for economic evaluations and budget impact analyses: second edition

2012 · External reference

Defining post-stroke recovery: implications for design and interpretation of drug trials

10.1016/s0028-3908(00)00003-4 · 2000 · External reference

Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study

10.1111/j.1524-4733.2005.04008.x · 2005 · External reference

Cost effectiveness analysis of varenicline (Champix) for the treatment of smoking in Spain

2008 · External reference

Treating tobacco use and dependence

2000 · External reference

Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation

10.1161/01.str.29.6.1083 · 1998 · External reference

Varenicline, smoking cessation, and neuropsychiatric adverse events

10.1176/appi.ajp.2013.12121599 · 2013 · External reference

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial

10.1001/jama.296.1.47 · 2006 · External reference

Re-treatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial

10.1038/clpt.2014.124 · 2014 · External reference

Unresolved reference

2010 · External reference

Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease

10.2165/00019053-200523020-00005 · 2005 · External reference

Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands

10.1185/030079908x242917 · 2008 · External reference

Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers

10.2165/00019053-200826060-00004 · 2008 · External reference

Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan

10.2165/00019053-200927030-00007 · 2009 · External reference

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

10.1001/jama.296.1.56 · 2006 · External reference

Varenicline. A pharmacoeconomic review of its use as an aid to smoking cessation

10.2165/11204380-000000000-00000 · 2010 · External reference

The cost-effectiveness of an extended course (12+12weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective

2012 · External reference

Smoking relapse after 2years of abstinence: findings from the VA Normative Aging Study

10.1080/14622200110098428 · 2002 · External reference

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers

10.1185/03007990903542666 · 2010 · External reference

Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model

10.3810/hp.2012.02.945 · 2012 · External reference

Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation

10.1111/j.1742-1241.2011.02877.x · 2012 · External reference

Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow-up study

10.1136/thorax.58.5.388 · 2003 · External reference

Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis

10.1161/circulationaha.113.003961 · 2014 · External reference

Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model

10.1016/s0021-9150(97)00321-3 · 1998 · External reference

Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis

10.5993/ajhb.32.6.10 · 2008 · External reference

Development of the health and economic consequences of smoking interactive model

10.1136/tc.10.1.55 · 2001 · External reference

De medische en niet-medische kosten van kankerpatiënten

2011 · External reference

Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies

10.1136/bmj.321.7257.323 · 2000 · External reference

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

10.2165/00019053-200523060-00008 · 2005 · External reference

Psychometric and utility-based measures of health status of asthmatic patients with different disease control level

10.2165/00019053-200422080-00005 · 2004 · External reference

Unresolved reference

External reference

A meta-analysis of quality-of-life estimates for stroke

10.2165/00019053-200321030-00004 · 2003 · External reference

Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom

10.1001/jama.284.6.706 · 2000 · External reference

Varenicline Phase 3 study Group, Effect of maintenance therapy with varenicline on smoking cessation : a randomized controlled trial

10.1001/jama.296.1.64 · 2006 · External reference

Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics

10.2165/00019053-200119080-00007 · 2001 · External reference

Effectiviteit en kosten-effectiviteit van behandlingen voor rookstop

2004 · External reference

Future burden and costs of smoking-related disease in the Netherlands: a dynamic modeling approach

10.1046/j.1524-4733.2003.64157.x · 2003 · External reference

Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials

10.1097/mjt.0b013e31828d455b · 2013 · External reference

Late relapse/sustained abstinence among former smokers: a longitudinal study

10.1016/j.ypmed.2004.04.028 · 2004 · External reference

An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy

10.1177/1741826711420345 · 2010 · External reference

A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities

10.1111/j.1365-2753.2010.01439.x · 2011 · External reference